Lancet HIV柳叶刀·艾滋病
Lancet HIV(英文缩写 LANCET HIV),ISSN 2352-3018,eISSN 2352-3018,中文译名:柳叶刀·艾滋病 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 16.070 | Q1 |
| 2022 | 16.100 | Q1 |
| 2023 | 12.800 | Q1 |
| 2024 | 13.000 | Q1 |
| 2025 | 14.600 | Q1 |
Lancet HIV 最新收录文献
-
2. Integrating long-acting injectable cabotegravir for HIV prevention into the Brazilian public health system (ImPrEP CAB Brasil): a hybrid type-2 implementation-effectiveness cohort study.
PMID:日期:2026-09-24Daily oral pre-exposure prophylaxis (PrEP) requires sustained adherence, which remains challenging in real-world settings. Although long-acting injectable cabotegravir (CAB-LA) could improve prevention coverage, implementation evidence in Latin America is scant. We evaluated the feasibility of integrating same-day CAB-LA delivery within Sistema Único de Saúde (SUS), the Brazilian public health system. ImPrEP CAB Brasil was a multicentre, hybrid type-2 implementation-effectiveness, open-label cohort study done at 14 PrEP public health services in six Brazilian cities. Eligible participants were cisgender men, non-binary people assigned male at birth, and transgender men and women who have sex with men, aged 18-30 years, who tested HIV negative, and were PrEP-naive. Participants could choose either CAB-LA (CAB-LA choice cohort) or oral PrEP with tenofovir disoproxil fumarate and emtricitabine (oral PrEP choice cohort), We included a comparison cohort of people initiating PrEP in SUS (oral PrEP SUS cohort). The main outcomes were HIV incidence and follow-up days covered by PrEP. For CAB-LA, we evaluated on-time injection adherence, switching, loss to follow-up, and safety. Participants were given the option to switch PrEP modalities or remain off PrEP during follow-up. Adverse events of special interest in participants using CAB-LA were assessed at every study visit. The study was registered at ClinicalTrials.gov (NCT05515770) and is ongoing. Participants were enrolled from Oct 17, 2023, to Sept 16, 2024, and followed up until Oct 16, 2025. 3096 participants were included in this analysis: 1201 (38·8%) in the CAB-LA choice cohort, 246 (7·9%) in the oral PrEP choice cohort, and 1649 (53·3%) in the oral PrEP SUS cohort. Most participants were cisgender men (2893 [90·9%]), Pardo or Black (1663 [53·7%]), and completed secondary education or higher (2517 [81·3%]). Median age was 26 years (IQR 23-28). HIV incidence was 0·20 per 100 person-years (95% CI 0·04-0·57) for the CAB-LA cohort (three new HIV infections), 0·87 (0·11-3·16) for the oral PrEP choice cohort (two new HIV infections), and 1·48 (0·88-2·33) for the oral PrEP SUS cohort (18 new HIV infections). 590 091 (90·8%) follow-up days were covered by PrEP in the CAB-LA cohort versus 69 491 (47·3%) in the oral PrEP choice cohort and 328 025 (35·5%) in the oral PrEP SUS cohort (p<0·0001). 107 (8·8%) of 1220 participants were lost to follow-up in the CAB-LA cohort, and were mainly people who were non-White, had lower levels of education, and had moderate or severe depressive symptoms. On-time injection adherence was high (92%). Injection-site reactions were the most frequent adverse event (4212 events in 1067 [87·5%] participants) and were generally mild to moderate. 80 serious adverse events were reported: 43 adverse events of interest (one related to CAB-LA) and 37 other events (none related to CAB-LA). Same-day CAB-LA delivery effectively reduced HIV incidence and increased PrEP coverage, supporting the implementation of long-acting options within SUS in Brazil. Unitaid, WHO, and Ministry of Health of Brazil. For the Portuguese and Spanish translations of the abstract see Supplementary Materials section.
-
3. Psychedelic-assisted therapy research for people with HIV.
3. 针对HIV感染者的致幻剂辅助疗法研究PMID:日期:2026-09-22该文献暂无摘要。
-
4. Trends in HIV-1 transmission in Switzerland: a retrospective molecular epidemiology study.
PMID:日期:2026-09-21The rapid identification of emerging transmission clusters could help reach the 2030 goal of halting transmission of HIV in Switzerland. We characterised the size, structure, and growth of recent HIV-1 transmission clusters in the Swiss HIV Cohort Study (SHCS). In this retrospective molecular epidemiology analysis in Switzerland, we analysed 32 294 HIV-1 pol sequences from 16 428 SHCS participants, enrolled between Aug 14, 1984, and May 19, 2025. Sequences were aligned and clustered using a 0·01 Tamura-Nei 93 distance threshold, and networks were constructed at the participant level to identify clusters and their growth. We defined and described a set of fast-growing clusters of HIV in Switzerland. Associations between clustering, demographic and clinical characteristics, and viral suppression were assessed. 7387 (45·0%) participants were part of 1131 clusters. Cluster size distribution was highly skewed: 62% contained only two individuals, whereas a few large clusters accounted for thousands of participants. The epidemic fragmented from a single dominant cluster of people who inject drugs in the 1990s into numerous smaller clusters, predominantly among gay, bisexual, and other men who have sex with men (MSM). Since 2016, 32·6% of the total cluster growth was concentrated in a set of 23 fast-growing clusters. These fast-growing clusters mostly comprised western European MSM with high rates of condomless sex. Cluster growth was strongly associated with viraemia among connected participants. The Swiss HIV epidemic has evolved into fragmented, short transmission chains, with a small number of fast-growing clusters sustaining ongoing transmission. Molecular surveillance can identify such clusters, enabling tailored interventions that complement treatment as prevention. Achieving zero HIV transmission in Switzerland will require integration of molecular epidemiology into routine prevention. Swiss National Science Foundation.
-
5. Turkish Government crackdown on HIV and LGBTQ+ groups.
5. 土耳其政府镇压艾滋病病毒和LGBTQ+群体PMID:日期:2026-09-18该文献暂无摘要。
-
6. Expediting a UNIVERSAL first-line regimen of a dolutegravir-emtricitabine-tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity trial.
PMID:日期:2026-09-07Paediatric antiretroviral fixed-dose combination tablets remain limited. UNIVERSAL1 evaluated pharmacokinetics, short-term safety, and antiviral activity of novel fixed-dose ratios of dolutegravir, emtricitabine, and tenofovir alafenamide in children with HIV. UNIVERSAL1 was an open-label, single-arm, phase 1-2, pharmacokinetic, safety, and antiviral activity study. Children with HIV aged between 28 days and 10 years with a bodyweight between 3 kg and less than 25 kg were enrolled at three clinical research centres (one in Harare, Zimbabwe, and two in Kampala, Uganda). Children were enrolled across five WHO bodyweight bands (ten children per weight band) and received dolutegravir, emtricitabine, and tenofovir alafenamide at the following respective doses according to weight band: 5 mg, 15 mg, 1·88 mg (3 kg to <6 kg band); 15 mg, 45 mg, 5·64 mg (6 kg to <10 kg band); 20 mg, 60 mg, 7·52 mg (10 kg to <14 kg band); 25 mg, 75 mg, 9·4 mg (14 kg to <20 kg band); and 50 mg, 200 mg, 25 mg (20 kg to <25 kg band). Children weighing 3 kg to less than 20 kg received dispersible tablets with 10 mg dolutegravir and tablets for oral suspension with emtricitabine (15 mg)-tenofovir alafenamide (1·88 mg); children weighing 20 kg to less than 25 kg received film-coated tablets containing 50 mg dolutegravir and emtricitabine (200 mg)-tenofovir alafenamide (25 mg). Primary pharmacokinetic outcomes were the areas under the concentration time curve over the dosing interval from time 0 h to 24 h (AUC) for dolutegravir, emtricitabine, and tenofovir, and from time 0 h to time of the last measurable concentration of the dosing interval (AUC) for tenofovir alafenamide; maximum plasma concentration (C) for all four compounds; and concentration at the end of the dosing interval (C for dolutegravir, emtricitabine, and tenofovir and C for tenofovir alafenamide). Primary safety outcomes were the occurrence of serious adverse events; new clinical and laboratory grade 3 and 4 adverse events; and adverse events of any grade leading to treatment interruption, discontinuation, or modification. Pharmacokinetic parameters were determined by non-compartmental analysis. The number of children with dolutegravir C lower than 0·32 mg/L (EC), tenofovir alafenamide AUC lower than 55 h × ng/mL (antiviral activity target), and tenofovir AUC higher than 2586 h × ng/mL (toxicity target) is reported. The trial is completed and registered with ClinicalTrials.gov, NCT05993767. Between Jan 7 and June 5, 2025, 53 participants were enrolled (51 included in pharmacokinetic analysis, 53 included in safety analysis). Of these 53 children, 28 (53%) were female and 25 (47%) were male. Median age was 37 months (IQR 10-64), and median weight was 11·6 kg (7·9-16·8). Dolutegravir geometric mean (GM) value of AUC was 93·1 h × mg/L (percentage coefficient of variation 41), C was 7·2 mg/L (44), and C was 1·7 mg/L (55). No child had dolutegravir C lower than 0·32 mg/L. Emtricitabine GM of AUC was 11·1 h × mg/L (60), C was 1·6 mg/L (63), and C was 0·06 mg/L (46). Tenofovir alafenamide GM of AUC was 207·1 h × ng/mL (101), C 125·2 ng/mL (114), C 6·9 ng/mL (180). Three children had a tenofovir alafenamide AUC lower than 55 h × ng/mL. Tenofovir GM of AUC was 219·0 h × ng/mL (53), C 14·4 ng/mL (50), and C 6·9 ng/mL (66). None had tenofovir AUC higher than 2586 h × ng/mL. Adverse events were reported in 31 (58%) of the 53 participants. The overall incidence of adverse events was 3·7 events per 100 person-weeks (95% CI 2·5-5·2). Three (6%) participants experienced a serious adverse event (hospitalisation for severe malaria, severe acute malnutrition, and life-threatening anaemia); all serious adverse events were deemed unrelated to study drugs. One grade 3 adverse event (elevated aspartate aminotransferase) was considered possibly related to the study drugs. The patient with severe malnutrition (grade 4) had to have a dose reduction due to a change to a lower weight band; no other participants experienced adverse events that led to study drug withdrawal, interruption, or modification. These data support proposed dosing of the dispersible fixed-dose combination (dolutegravir [5 mg]-emtricitabine [15 mg]-tenofovir alafenamide [1·88 mg]) for children weighing between 3 kg and less than 20 kg and extension of the licensed film-coated tablet (dolutegravir [50 mg]-emtricitabine [200 mg]-tenofovir alafenamide [25 mg]) for children weighing 20 kg or over. Second European and Developing Countries Clinical Trials Partnership (EDCTP2).
-
9. Plasma dolutegravir exposure testing to identify people with HIV at highest risk for dolutegravir resistance (ITREMA-2): a two-centre, prospective implementation study in South Africa.
PMID:日期:2026-09-02Dolutegravir resistance is increasingly reported in treatment-experienced people with HIV in low-income and middle-income countries. Resistance testing resources are sparse, and viral rebound often reflects adherence lapses rather than resistance. Efficient strategies are needed to target testing to individuals at highest risk. We evaluated a reflex laboratory approach using plasma dolutegravir exposure to guide resistance testing in routine care. In this prospective implementation study at two public-sector clinics in Johannesburg, South Africa, we analysed adults (aged ≥18 years) on dolutegravir-based antiretroviral therapy (ART) with viral rebound of 400 copies per mL or higher. From May 18, 2023, to Jan 10, 2025, we tested residual routine viral load samples for dolutegravir exposure using an enzyme immunoassay. If dolutegravir was detectable (≥20 ng/mL), we did reflex resistance testing on the same specimen; retrospective sequencing was done at study end for dolutegravir-undetectable samples. We modelled costs comparing the reflex approach with standard of care. We analysed 400 samples from 288 individuals; 160 (56%) were female and 128 (44%) male, the median age was 44 years (IQR 35-50), and 240 (83%) had previous non-dolutegravir ART exposure. Plasma dolutegravir was detectable in 108 (38%) participants. Among those with successful sequencing, dolutegravir resistance occurred in 13 (13%) of 102 participants with detectable dolutegravir and three (2%) of 138 with undetectable dolutegravir, yielding an overall prevalence of 6·7% dolutegravir resistance and a negative predictive value for absence of dolutegravir resistance of 97·8% (95% CI 93·5-99·5). Dolutegravir resistance was associated with detectable dolutegravir (odds ratio [OR] 3 [95% CI 1-9], p=0·031), nucleoside reverse transcriptase inhibitor mutations (OR 33 [4-264], p=0·0009), non-nucleoside reverse transcriptase inhibitor mutations (OR 17 [2-135], p=0·0068), or M184V (OR 20 [4-92], p=0·0002). Cost modelling showed a 23% reduction in monitoring cost per person using the reflex strategy after confirmed viraemia versus current national guidelines. Laboratory-initiated reflex plasma dolutegravir exposure testing provides an objective, cost-efficient strategy to predict the absence of dolutegravir resistance and supports adherence management, enabling timely, individualised treatment decisions. Reflex dolutegravir exposure testing could enhance clinical decision making, improve treatment outcomes, and strengthen HIV treatment and resistance monitoring algorithms in programmatic settings. The Amsterdam Dinner Foundation and Aidsfonds, the Netherlands Organisation for Scientific Research, ZonMw, and WOTRO.
-
10. Epidemiology and management of HIV-2.
PMID:日期:2026-08-26HIV-2 remains a neglected component of the global HIV epidemic, predominantly affecting west Africa but also present in Europe and other regions through historical and migratory links. Although generally characterised by lower transmissibility and slower disease progression than HIV-1, HIV-2 poses distinct diagnostic, therapeutic, and programmatic challenges. Research, implementation, and advocacy efforts aimed at reducing HIV-2 infection must account for the limitations of available typing tools, the restricted access to validated viral load assays, the virus' intrinsic resistance to certain antiretroviral drug classes, and the gaps in retention in care that hinder progress towards global treatment targets. Strengthening collaborative research, improving diagnostic capacity, and integrating HIV-2 into broader HIV policy frameworks are essential to optimise patient outcomes and to advance the global HIV response.